文献速递中枢神经肿瘤放疗放疗物理与技术

胶质母细胞瘤放疗前代谢异质性是否能预测无进展生存期

Is pre-radiotherapy metabolic heterogeneity of glioblastoma predictive of progression-free survival?
PubMed 文献 · Radiother Oncol · 2023-04-05

该研究基于前瞻性SPECTRO-GLIO试验中180例胶质母细胞瘤患者放疗前质子磁共振波谱成像数据,提取8项代谢特征并用小批量k均值聚类识别出5个代谢异质性聚类,其中2个聚类显示代谢异常,聚类2为主导时无进展生存期(PFS)较低,乳酸是最具统计学显著性的不良结局预测因子。

要点

  • 放疗前质子磁共振波谱成像可揭示胶质母细胞瘤的肿瘤代谢异质性。
  • 180例患者中识别出5个代谢聚类,其中2个聚类显示代谢异常。
  • 聚类2为主导聚类时PFS较低,乳酸是最具统计学显著性的不良结局预测因子。

核心结论

  • 放疗前MRSI可揭示肿瘤异质性,具有相同代谢信息的波谱组反映代表肿瘤负荷增殖和缺氧的不同组织成分。
  • 具有代谢异常和高乳酸的聚类可预测PFS。

研究设计与样本

  • 前瞻性SPECTRO-GLIO试验纳入180例患者放疗前检查获取的MRSI数据。
  • 每个波谱提取8项特征:Cho/NAA、NAA/Cr、Cho/Cr、Lac/NAA及各代谢物与所有代谢物之和的比值。
  • 采用小批量k均值算法对数据进行聚类,使用Cox模型和logrank检验分析PFS。

主要发现

  • 识别出5个具有相似代谢信息且可预测PFS的聚类,其中2个聚类显示代谢异常。
  • 当聚类2为患者MRSI数据中的主导聚类时,PFS较低。
  • 乳酸(存在于该聚类和聚类5中)是预后不良最具统计学显著性的预测因子。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: All glioblastoma subtypes share the hallmark of aggressive invasion, meaning that it is crucial to identify their different components if we are to ensure effective treatment and improve survival. Proton MR spectroscopic imaging (MRSI) is a noninvasive technique that yields metabolic information and is able to identify pathological tissue with high accuracy. The aim of the present study was to identify clusters of metabolic heterogeneity, using a large MRSI dataset, and determine which of these clusters are predictive of progression-free survival (PFS). MATERIALS AND METHODS: MRSI data of 180 patients acquired in a pre-radiotherapy examination were included in the prospective SPECTRO-GLIO trial. Eight features were extracted for each spectrum: Cho/NAA, NAA/Cr, Cho/Cr, Lac/NAA, and the ratio of each metabolite to the sum of all the metabolites. Clustering of data was performed using a mini-batch k-means algorithm. The Cox model and logrank test were used for PFS analysis. RESULTS: Five clusters were identified as sharing similar metabolic information and being predictive of PFS. Two clusters revealed metabolic abnormalities. PFS was lower when Cluster 2 was the dominant cluster in patients' MRSI data. Among the metabolites, lactate (present in this cluster and in Cluster 5) was the most statistically significant predictor of poor outcome. CONCLUSION: Results showed that pre-radiotherapy MRSI can be used to reveal tumor heterogeneity. Groups of spectra, which have the same metabolic information, reflect the different tissue components representative of tumor burden proliferation and hypoxia. Clusters with metabolic abnormalities and high lactate are predictive of PFS.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Tensaouti F, Desmoulin F, Gilhodes J, et al. Is pre-radiotherapy metabolic heterogeneity of glioblastoma predictive of progression-free survival? Radiother Oncol. 2023. PMID: 37024057. doi:10.1016/j.radonc.2023.109665

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。